Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of DS-3201b in Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

NCT03110354 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT03110354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03110354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of DS-3201b in Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
April 5, 2017
Completion date
March 9, 2021
Enrollment
28 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, acute, leukemia, myeloid, acute